Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24732017 | 0.84 | KMT2A (0.58) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| SCHEMBL18390001 | 0.82 | MEN1 (0.69) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| SCHEMBL14476103 | 0.82 | MEN1 (0.73) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| SCHEMBL13604236 | 0.80 | KMT2A (0.71) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| SCHEMBL12204584 | 0.80 | ALDH1A1 (0.76) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| SCHEMBL15965548 | 0.79 | ALDH1A1 (0.60) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| SCHEMBL6245041 | 0.78 | KMT2A (0.67) | MEN1KMT2AALDH1A1MAPK1SIGMAR1 | |
| SCHEMBL18705122 | 0.77 | KMT2A (0.61) | MEN1KMT2AALDH1A1MAPK1HTR7 | |
| Hydrochloric Acid SCHEMBL2827786 | 0.76 | KMT2A (0.65) | MEN1KMT2AALDH1A1MAPK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL11529235 | 0.76 | KMT2A (0.97) | MEN1KMT2AALDH1A1SIGMAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | MEN1 4261/4885KMT2A 4292/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.